> Detailanzeige

Amendola, Antonella; Boschini, Antonio; Colzani, Daniela; Anselmi, Giovanni; Oltolina, Arianna; Zucconi, Roberta; Begnini, Marco; Besana, Silvia; Tanzi, Elisabetta; Zanetti, Alessandro Remo

Influenza vaccination of HIV‐1‐positive and hiv‐1‐negative former intravenous drug users

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Influenza vaccination of HIV‐1‐positive and hiv‐1‐negative former intravenous drug users
  • Beteiligte: Amendola, Antonella; Boschini, Antonio; Colzani, Daniela; Anselmi, Giovanni; Oltolina, Arianna; Zucconi, Roberta; Begnini, Marco; Besana, Silvia; Tanzi, Elisabetta; Zanetti, Alessandro Remo
  • Erschienen: Wiley, 2001
  • Erschienen in: Journal of Medical Virology, 65 (2001) 4, Seite 644-648
  • Sprache: Englisch
  • DOI: 10.1002/jmv.2085
  • ISSN: 0146-6615; 1096-9071
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: AbstractThe immunogenicity of an anti‐influenza vaccine was assessed in 409 former intravenous drug user volunteers and its effect on the levels of HIV‐1 RNA, proviral DNA and on CD4+ lymphocyte counts in a subset HIV‐1‐positive subjects was measured. HIV‐1‐positive individuals (n = 72) were divided into three groups on the basis of their CD4+ lymphocyte counts, while the 337 HIV‐1‐negative participants were allocated into group four. Haemagglutination inhibiting (HI) responses varied from 45.8 to 70% in the HIV‐1‐positive subjects and were significantly higher in group four (80.7% responses to the H1N1 strain, 81.6% to the H3N2 strain, and 83% to the B strain). The percentage of subjects with HI protective antibody titres (≥ 1:40) increased significantly after vaccination, especially in HIV‐1 uninfected subjects. Immunization caused no significant changes in CD4+ counts and in neither plasma HIV‐1 RNA nor proviral DNA levels. Therefore, vaccination against influenza may benefit persons infected by HIV‐1. J. Med. Virol. 65:644–648, 2001. © 2001 Wiley‐Liss, Inc.